US Stock Insider Trading | Nurix Therapeutics disclosed 1 insider transaction on February 3rd

2026-02-12 15:29:33

Abstract generation in progress

On February 3, 2026, Nurix Therapeutics (NRIX) disclosed one insider transaction. Executive Hansen Gwenn purchased 31,300 shares.

[Recent Insider Transactions]

Disclosure Date	Position	Name	Transaction Date	Buy/Sell	Quantity	Price per Share/USD	Total Amount/USD
February 3, 2026	Executive	Hansen Gwenn	February 3, 2026	Buy	31,300	0.84	26,300
January 30, 2026	Executive	Ring Christine	January 30, 2026	Sell	4,333	16.58	71,900
January 30, 2026	Executive	Ring Christine	January 30, 2026	Sell	88	17.37	1,528.71
January 30, 2026	Executive	van Houte Hans	January 30, 2026	Sell	73	17.37	1,268.13
January 30, 2026	Executive	Hansen Gwenn	January 30, 2026	Sell	98	17.37	1,702.43
January 30, 2026	Executive	Hansen Gwenn	January 30, 2026	Sell	4,797	16.58	79,500
January 30, 2026	Executive	van Houte Hans	January 30, 2026	Sell	3,588	16.58	59,500
January 20, 2026	Executive	Ring Christine	January 20, 2026	Buy	3,760	1.86	6,993.60
January 20, 2026	Executive	Ring Christine	January 20, 2026	Sell	3,760	18.42	69,300
December 18, 2025	Executive	Ring Christine	December 18, 2025	Buy	3,760	1.86	6,993.60

[Company Information]

Nurix Therapeutics, Inc. was incorporated on August 27, 2009, in Delaware, with headquarters in Brisbane, California. It is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted protein degradation medicines aimed at improving treatment options for cancer and inflammatory diseases. Supported by an AI-integrated discovery engine and deep expertise in E3 ligase biology, the company advances a differentiated approach to translating protein degradation science into clinical therapies. Nurix’s wholly owned pipeline includes investigational candidates targeting Bruton’s tyrosine kinase (BTK) and Casitas B-lineage lymphoma proto-oncogene B (CBL-B), along with additional degraders and degrader antibody-drug conjugates in preclinical development. Nurix collaborates with global pharmaceutical partners including Gilead Sciences, Sanofi, and Pfizer, conducting discovery programs for multiple candidates under co-development and co-commercialization arrangements.

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.